Randomized trial: IpsiHand BCI helps stroke survivors regain arm function years after stroke
In 62 chronic stroke survivors, 55.5% of those using the EEG-based BCI had clinically meaningful recovery versus 9.6% of controls.
Results presented at the International Stroke Conference 2026 show the FDA-cleared IpsiHand system improved arm function in 62 chronic stroke survivors, an average of 5.4 years after their stroke. The non-invasive BCI uses EEG to detect movement intention and drive a hand exoskeleton. On a standard arm-function scale, the BCI group improved by 6.0 points versus 1.5 for controls, and 55.5% reached clinically meaningful recovery versus 9.6%.
The study was led by Eric Leuthardt, chief scientific officer of Kandu, which now markets IpsiHand. It adds randomized evidence that neuroplasticity can still be tapped years after a stroke.
Learn more: Motor imagery · Neurolutions (IpsiHand)